Publication in detail

Br J Pharmacol 2011 Sep 6. doi: 10.1111/j.1476-5381.2011.01659.x. [Epub ahead of print]

Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma.

May, R; Monk, P; Cohen, E; Manuel, D; Dempsey, F; Davis, N; Dodd, A; Corkill, D; Woods, J; Joberty-Candotti, C; Conroy, L; Koentgen, F; Martin, E; Wilson, R; Brennan, N; Powell, J; Anderson, I.

MedImmune, Abington, Cambridge, UK.

Background and purpose:  IL-13 is a pleiotropic Th2 cytokine considered likely to play a pivotal role in asthma. This paper describes the preclinical in vitro and in vivo characterisation of CAT-354, an IL-13-neutralising IgG4 mAb, which is currently in clinical development. Experimental approach:  In vitro the potency, specificity, and species selectivity of CAT-354 was assessed in TF-1, HUVEC, and HDLM2 cell-based assays. The ability of CAT-354 to modulate disease relevant mechanisms was tested in bronchial smooth muscle calcium flux, NHLF eotaxin generation, PBMC CD23 upregulation, and B cell IgE production assay systems. In vivo CAT-354 was tested in huIL-13-induced air pouch inflammation, IL-13 humanised mouse ovalbumin-sensitisation and challenge, and cynomolgus monkey antigen challenge models. Key results:  CAT-354 has a 165pM affinity for human IL-13 and functionally neutralises human, human variant associated with asthma and atopy (Q130R), and cynomolgus monkey, but not mouse IL-13. CAT-354 is selective for human IL-13 and does not neutralise IL-4. In vitro CAT-354 functionally inhibits IL-13-induced eotaxin production, an analogue of smooth muscle AHR, CD23 upregulation, and IgE production. In vivo, in humanised mouse and cynomolgus antigen challenge models, CAT-354 inhibits antigen-challenge induced AHR and BAL eosinophilia. Conclusions and implications:  CAT-354 is a potent and selective IL-13-neutralising IgG4 mAb. The preclinical data presented here support the trialling of this mAb in patients with moderate-severe uncontrolled asthma.

» Online Version

Proven Track Record

The team at Ozgene has over two decades of experience creating customised knockout and knock-in mice for pivotal medical research globally. Over 400 scientific publications are based on research using Ozgene mice.

Go to Publications

Global Client Base

Ozgene generates genetically customised mice for researchers around the world. Ozgene mice can be found in 31 different countries on 5 continents from small academic institutions to multinational pharmaceutical companies.

See Client Papers

Lean Management

Ozgene is applying Lean Management principles to deliver the highest quality services and shortest lead times to our customers. The implementation of Lean Culture has already seen an improvement in our processes and timelines.

Read More